49 results about "Left Ventricle Remodeling" patented technology

The invention discloses application of melastoma dodecandrum lour in preparation of antihypertensive drugs and drugs for treating hypertension complications. It is found for the first time that by means of melastoma dodecandrum extract treatment, AKT1 and EGFR protein expression related to hypertension can be lowered, blood pressure (Plt, 0.05) and cardiac fibrosis degree (Plt, 0.01) of spontaneously hypertensive rats (SHR) can be remarkably lowered, inflammatory response (Plt, 0.05) can be inhibited, and the effect of treating the melastoma dodecandrum extract can be achieved. The melastoma dodecandrum not only has the effect of reducing blood pressure, but also has the functions of improving myocardial fibrosis and inhibiting inflammatory response; moreover, the melastoma dodecandrum lour has no toxic or side effect on the body, is safe and reliable to use, shows that the melastoma dodecandrum lour has good research and development prospects of reducing blood pressure, improving myocardial fibrosis and resisting ventricular remodeling, and provides a new effective way for hypertension and corresponding complications.

The invention discloses application of an HIF1A inhibitor in preparation of a medicine for preventing and / or treating hypertrophic cardiomyopathy, and belongs to the field of biological medicine. For a rat model of spontaneous hypertrophic cardiomyopathy caused by MYH7B gene knockout, hypertrophic cardiomyopathy can be significantly relieved by intraperitoneal injection of the HIF1A inhibitor LW6, heart remodeling can be relieved, heart functions can be improved, and myocardial hypertrophy caused by silent MYH7B genes can be effectively resisted by using siRNA of mRNA transcribed by the HIF1A gene. The key mechanism of the HIF1A inhibitor for treating the hypertrophic cardiomyopathy is that the hypertrophic cardiomyopathy is prevented and treated by reducing the expression level of glycolysis key enzymes GLUT1, HK2 and the like, inhibiting the formation and accumulation of cardiac lactic acid and improving the ventricular remodeling of the hypertrophic cardiomyopathy. The results show that the HIF1A inhibitor can be used for treating and / or preventing the human hypertrophic cardiomyopathy and has the potential of being developed into the medicine for clinically preventing and treating the hypertrophic cardiomyopathy.

The invention discloses application of Axl in treatment of right heart failure ventricular remodeling. The invention relates to application of a substance for regulating Axl expression in preparation of a product for remodeling the structure and function of a right ventricle. The substance for regulating the expression of the Axl is used for overexpressing the Axl or inhibiting the expression of the Axl. Regulation and control of Axl target spots can significantly improve right ventricular remodeling, delay disease progression of right heart failure and improve the survival rate of patients.

The application discloses a kind of short peptides simulating RhoE C end, derivative and its pharmaceutical use in treating ventricular remodeling, belong to biological medicine technical field.The short peptide and derivative contain RhoE C end 200-240 linear function domain, can be combined and activated WWP2, remove HGS self-inhibition, start endosome-lysosome degradation pathway.Short peptide sequence is as SEQ ID NO.1, derivative can be coupled with TAT, T7 or RVG membrane penetrating peptide (SEQ ID NO.2-4), and endocytosed to myocardial cell by caveolin high efficiency delivery.The application solves the defects that existing anti-ventricular remodeling drug inhibits protective autophagy flow, and the ability of eliminating toxic protein is limited, can efficiently eliminate damaged mitochondria and misfolded protein, inhibits myocardial hypertrophy, fibrosis, improves cardiac remodeling, provides safe and effective treatment strategy for related diseases.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for preventing and treating ventricular remodeling and a preparation method thereof. The traditional Chinese medicine composition for preventing and treating ventricular remodeling is prepared from the following raw materials: 25 to 35 parts of radix astragali seu hedysari, 10 to 15 parts of cassia twig, 10 to 15 parts of peach kernel, 12 to 18 parts of flos carthami and 7 to 11 parts of semen lepidii. According to the traditional Chinese medicine composition, the left ventricular posterior wall thickness, the ventricular septum thickness and the left ventricular end diastolic inner diameter are obviously increased, the left ventricular end systolic inner diameter, the left ventricular mass index and the right ventricular mass index are obviously reduced, and it is prompted that the traditional Chinese medicine composition can inhibit ventricular remodeling of rats suffering from ischemic cardiomyopathy.

The invention discloses a motion intervention heart failure repair method based on Lgmn signal regulation and control, and relates to the technical field of heart failure treatment. According to the method, through aerobic exercise training (AET) with specific parameters, expression of Legumain (Lgmn) genes in macrophages is regulated in a targeted mode, the interburial effect of the macrophages is enhanced, then cell communication between the macrophages and cardiac muscle cells is enhanced, removal of the vertical death cardiac muscle cells is promoted, myocardial fibrosis and inflammatory response are relieved, and the effect of treating myocardial fibrosis is achieved. Finally, ventricular remodeling and heart functions of chronic heart failure (CHF) mice are improved. Experimental verification shows that the exercise intervention method can significantly improve the left ventricular ejection fraction (LVEF) and shortening fraction (FS) of CHF model animals, reduce the left ventricular end-of-systole inner diameter (LVESD), reduce myocardial cell apoptosis and necrosis, and promote inflammation regression. Drug intervention is not needed, safety is high, operation is easy and convenient, and a new effective way is provided for clinical rehabilitation treatment of heart failure.

The present invention discloses the use of a traditional Chinese medicine composition in the preparation of a drug for preventing or treating diabetic cardiomyopathy. The traditional Chinese medicine composition of the present invention is composed of notopterygium root, angelica dahurica, Poria cocos, saposhnikovia root, schizonepeta tenuifolia, ligusticum wallichii, chuanxiong rhizome, platycodon grandiflorum, bupleurum root, peucedanum chinense, fructus aurantii, and liquorice. Pharmacodynamic experimental results show that the traditional Chinese medicine composition of the present invention can reduce serum creatine kinase isoenzyme (CK-MB) and lactate dehydrogenase (LDH) levels, and can significantly improve diabetic myocardial cell damage; reduce cardiac index, improve myocardial hypertrophy and left ventricular remodeling, and has the effect of preventing and treating diabetic cardiomyopathy.

The present invention relates to the field of medical devices, and in particular to an adjustable and removable valve clamping device, the valve clamping device comprising a fixing portion and a spacer portion, the fixing portion comprising a support member, an anchor member and a connector, the spacer portion comprising a connected balloon body and a variable valve, the support member, the anchor member and the balloon body being all connected to the connector. The valve clamping device of the present invention can adapt to anatomical structures of various nonlinear sizes, expanding the scope of indications; it can provide a re-intervention interface after the anatomical dimensions around the mitral valve change after surgery, adjust the clamping distance and tension, thereby alleviating reflux caused by postoperative left ventricular remodeling and further prolonging the treatment effect; each component provides a reliable clamping structure and reduces reflux at the beginning of implantation, and some structures can degrade after a period of time after surgery, providing space for other treatment methods such as replacement that may be required for long-term prognosis.

The invention provides a heart implant, a delivery assembly and a heart implant system.The heart implant comprises a valve prosthesis and an anchoring nail, the anchoring nail can nail the valve prosthesis on a native tissue of an atrioventricular valve, on one hand, anchoring of the valve prosthesis in the heart is achieved, the problems of falling, shifting, twisting and the like of the valve prosthesis are avoided, and the heart implant delivery efficiency is improved; on the other hand, the compression of the valve prosthesis on the native tissue of the heart is greatly reduced so as to solve a series of problems such as ventricular structure remodeling caused by the valve prosthesis anchored through radial force, and on the other hand, the fitting gap between the valve prosthesis and the native tissue can be reduced, the sealing performance of the perivalvular is improved, the perivalvular leakage is reduced, and the heart safety is improved. On the other hand, when the valve prosthesis is nailed on the valve ring of the atrioventricular valve through the anchoring nail, the valve prosthesis is allowed to have a small axial height, and therefore the height of the valve prosthesis below the valve is reduced, and blocking of the valve prosthesis to blood entering the ventricular outflow tract is reduced.

The invention provides application of a product for supplementing Lrrc52 in preparation of a medicine for preventing and / or treating myocardial ischemia-reperfusion injury, and belongs to the technical field of biological medicine. The invention provides an application of a product for supplementing Lrrc52 as a medicine for preventing and / or treating myocardial ischemia-reperfusion injury, Lrrc52 protein is supplemented into a body, so that the apoptosis and necrosis degree of myocardial cells after myocardial ischemia-reperfusion can be effectively relieved, the pathological ventricular remodeling process is restrained, the cardiac fibrosis condition is relieved, the cardiac function is enhanced, and the myocardial ischemia-reperfusion injury can be prevented and treated. And therefore, heart-related diseases such as acute ischemia-reperfusion injury, pathological ventricular remodeling and heart failure can be prevented and treated. The invention clearly reveals the potential of overexpression Lrrc52 in the aspect of improving myocardial ischemia reperfusion injury for the first time, opens up a brand new drug research and development road and an action target for prevention and treatment of the disease, and shows extremely high medicinal value and significance.

The application discloses a traditional Chinese medicine composition for treating dilated cardiomyopathy, relates to the field of traditional Chinese medicines, and provides a traditional Chinese medicine composition for improving ventricular remodeling of a dilated cardiomyopathy patient, which is prepared from the following traditional Chinese medicines in parts by weight: radix astragali 60-90 parts, semen platycladi 15-30 parts, cortex mori 15-30 parts, ramulus cinnamomi 10-15 parts, zingiberis rhizoma siccum 10-15 parts, curcuma zedoaria 10-20 parts, cinnamomum cassia 6-10 parts and euonymus alatus 10-15 parts. The application has remarkable advantages in improving heart failure symptoms of the DCM patient, reversing ventricular remodeling, improving exercise tolerance, controlling arrhythmia and improving long-term prognosis of the patient.

The invention relates to application of arginine diester in preparation of a medicine for preventing and treating cardiovascular diseases, and belongs to the technical field of biological medicines. The invention provides an application of arginine diester in preparation of a medicine for preventing and treating cardiovascular diseases, the structural formula of the arginine diester is as shown in formula I, and y is 2, 3, 4 or 6. According to the arginine diester, the bioavailability of arginine in local cells of the heart is remarkably improved, the biological effect is more effectively played, and the arginine diester has higher heart targeting property and more effectively acts on heart tissues. The composition can significantly improve cardiac function indexes such as ejection fraction, short axis shortening rate and the like of the heart after myocardial infarction and ventricular remodeling, enhance the systolic function of the heart, improve cardiac hypertrophy, reduce the fibrosis area of the heart after myocardial infarction and increase the proportion of cardiac repair type macrophages after myocardial infarction, and is high in biological safety. The long-term treatment cost of cardiovascular diseases is reduced, the medical cost is reduced, and the overall health state and life quality of patients are improved.

The invention relates to the field of biological medicine, in particular to a si-RNA composition for inducing cardiac fibroblasts to transdifferentiate into endothelial cells and application of the si-RNA composition. The si-RNA composition comprises a si-RNA (Ribonucleic Acid) aiming at a gene Huwe1, a si-RNA aiming at a gene Ltbp3, a si-RNA aiming at a gene Dysf and a si-RNA aiming at a gene Hivep3. The HLDH (Huwe1, Ltbp3, Dysf and Hive3) combined knockout can be used for successfully inducing the transformation of fibroblasts into endothelial cells in an in-vitro ischemia and hypoxia state. A carrier containing shRNA capable of expressing and generating the si-RNA composition is delivered into the heart, so that cardiac fibroblasts undergo transdifferentiation in vivo and participate in angiogenesis, and therefore, increase of fibrosis area and adverse ventricular remodeling after myocardial ischemia are limited through ways such as fibrosis remodeling, the heart function is retained, and myocardial ischemia is improved and repaired.

Methods and materials for treating chronic cardiac disorders are provided herein. For example, methods and materials for using a dual guanylate cyclase A and B activator (e.g., a polypeptide having the sequence set forth in SEQ ID NO:1) to treat hypertrophic cardiomyopathy and other cardiac conditions, such as conditions associated with ventricular hypertrophy, atrial hypertrophy, ventricular remodeling, atrial remodeling, systolic and / or diastolic dysfunction, heart failure (e.g., heart failure with reduced ejection fraction, heart failure with mildly reduced ejection fraction, and heart failure with preserved ejection fraction), and other forms of chronic heart disease (e.g., Fabry disease, Noonan syndrome, Pompe disease, PRKAG2-related cardiomyopathy, Danon disease, Friedrich ataxia cardiomyopathy, amyloidosis, or desminopathy) are provided herein.

The invention belongs to the technical field of biological medicine, and particularly relates to composite hydrogel for promoting hiPSC-CMs in-situ maturation and a preparation method and application thereof. According to the preparation method disclosed by the invention, a compound liposome modified by quaternary ammonium chitosan and loaded with Torrin 1 is constructed, a unique three-dimensional network structure (PDN) is constructed by compounding different chitosan, and the compound liposome and the PDN are combined to obtain the composite hydrogel for embedding and delivering hiPSC-CMs. Wherein residual amine of the quaternary ammonium chitosan can slowly release drugs in an acidic microenvironment after myocardial infarction, and the cell cycle is inhibited; the PDN structure enhances the retention rate of cell transplantation; the loaded hiPSC-CMs can restore the contraction function, reduce spontaneous depolarization and action potential, reduce the risk of lethal arrhythmia and promote in-situ maturation of transplanted cells. Experiments show that the gel loaded with the hiPSC-CMs can significantly promote myocardial tissue maturation after myocardial infarction, effectively slow down ventricular remodeling and improve heart functions.

The invention discloses a function and application of a lysine deficiency type protein kinase 2 inhibitor in inhibition of ventricular remodeling, and belongs to the field of functions and application of genes. According to the invention, the mutual relation between the expression of the WNK2 and the ventricular remodeling is determined, and the research result shows that the expression of the WNK2 is obviously improved compared with that of a normal group in a model with pathological ventricular remodeling; the ventricular remodeling including cardiac hypertrophy, fibrosis and heart function decline is remarkably relieved by inhibiting the expression of the WNK2, and the ventricular remodeling process is remarkably intensified and the heart function is deteriorated by promoting the overexpression of the WNK2. The WNK2 can be used as a drug target and used for screening drugs for protecting heart functions, resisting myocardial fibrosis and / or preventing, relieving and / or treating ventricular remodeling and related heart diseases, and an inhibitor of the WNK2 can be used for developing drugs for protecting heart functions, inhibiting ventricular remodeling and preventing, relieving and / or treating ventricular remodeling related diseases. And an effective new way is provided for clinical treatment of ventricular remodeling.

This invention discloses the application of a Trichinella spiralis cysteine ​​protease inhibitor in acute myocardial infarction and subsequent ventricular remodeling, belonging to the field of medicinal chemistry. This invention provides a drug that can prevent, alleviate, and / or treat acute myocardial infarction and subsequent ventricular remodeling. The active ingredient of this drug is the Trichinella spiralis cysteine ​​protease inhibitor cystatin, abbreviated as rTs-Cys. rTs-Cys can effectively delay acute myocardial infarction and inflammatory response in mice, reduce the infarct area, improve cardiac function deterioration, and reverse organ pathological damage, providing a new approach for the clinical treatment of acute myocardial infarction and subsequent ventricular remodeling.

The invention discloses application of a serine protease inhibitor A3 in preparation of a medicine for preventing and / or treating heart failure diseases. Experimental results show that the SERPINA3 can improve cardiac function reduction, improve ventricular remodeling, reduce myocardial fibrosis, inhibit proliferation and migration ability of cardiac fibroblasts, inhibit differentiation of the cardiac fibroblasts to myofibroblasts and inhibit extracellular matrix proteins. The serine protease inhibitor A3 can inhibit cardiac fibroblast activation and myocardial fibrosis, and provides a new treatment strategy and means for clinical treatment of intractable heart failure.

The invention discloses application of deferasirox in preparation of a medicine for preventing ventricular remodeling after acute myocardial infarction, and relates to the technical field of medicines, in particular to application of deferasirox in preparation of a medicine for preventing ventricular remodeling after acute myocardial infarction. The medicine plays a role in inhibiting ferroptosis and inflammatory reaction of myocardial cells so as to prevent ventricular remodeling after acute myocardial infarction; deerasirox plays an iron chelation role and an anti-oxidative stress injury role in the medicine so as to inhibit ferroptosis and inflammatory response of myocardial cells; the inhibition effect of the medicine on myocardial cell ferroptosis is that GPX4 protein is up-regulated; the dosage of deferasirox in the medicine is 30 mg / Kg every day; the deferasirox can prevent ventricular remodeling after myocardial infarction of mice by inhibiting ferroptosis and inflammatory response, including improvement of cardiac function indexes and reduction of myocardial infarction area, and a new idea and a new scheme are provided for clinical prevention of ventricular remodeling after acute myocardial infarction.

The invention provides a traditional Chinese medicine composition for treating heart failure and a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following components: 1-12 parts of rohdea japonica, 1-12 parts of codonopsis pilosula, 1-12 parts of astragalus membranaceus, 1-12 parts of cassia twig, 1-8 parts of bighead atractylodes rhizome, 1-12 parts of poria cocos, 1-12 parts of radix ophiopogonis, 2-14 parts of semen lepidii, 1-10 parts of radix aconiti lateralis preparata, 1-10 parts of schisandra chinensis, 1-12 parts of hairyvein agrimony, 1-10 parts of pseudo-ginseng, 1-12 parts of epimedium, 1-12 parts of leonurus, 1-10 parts of ligusticum wallichii, 2-14 parts of salvia miltiorrhiza, 2-12 parts of radix sophorae flavescentis and 1-8 parts of liquorice. The traditional Chinese medicine composition can enhance myocardial contractility, increase coronary artery blood flow volume, protect myocardial cells, improve heart functions, obviously improve the heart functions and left ventricular remodeling, discharge liquid retained at the time of heart failure, relieve the pre-load of the heart and relieve edema; load during cardiac contraction is reduced, and excessive work of the heart is avoided.

The invention relates to the technical field of disease treatment, in particular to application of cardiac macrophage USP9X serving as an intervention target to preparation of medicine for treating ischemic heart disease, polypeptide P7 and application of the polypeptide P7. The invention finds that the expression of Ubiquitin specific peptidase 9X-Linked, USP9X coupled with deubiquitinase X chromosome of heart macrophage is reduced in the first three days (inflammation period) after myocardial infarction, and the inhibition of USP9X promotes the macrophage to be transformed into proinflammatory type, and finally causes poor ventricular remodeling, so that the USP9X can be used as an intervention target of ischemic heart disease, and then polypeptide is screened, and the application of the USP9X in the treatment of ischemic heart disease is realized. The degradation of USP9X after myocardial infarction is effectively inhibited, so that the excessive inflammatory response of macrophages after myocardial infarction is relieved.

The invention discloses application of cinnamic acid in preparation of a medicine for preventing or treating myocardial infarction chronic-stage pathological injury, and relates to the technical field of medicines. A coronary artery ligation animal model is used for simulating a chronic-stage pathological injury process after myocardial infarction, the cinnamic acid is subjected to gavage intervention, and various detection methods are used for evaluating the intervention effect of the cinnamic acid, so that the cinnamic acid is proved to have a remarkable curative effect on chronic-stage myocardial fibrosis, ventricular remodeling and heart failure after myocardial infarction for the first time; the invention further provides the application of the cinnamic acid in preparation of the medicine for preventing or treating myocardial infarction chronic-stage pathological injury, and compared with previous researches, the application range of the cinnamic acid is expanded, so that the application research of the cinnamic acid and the research and development of the medicine for myocardial infarction are both of great significance to application research of the cinnamic acid and research and development of the medicine for myocardial infarction.

The invention discloses application of GANT61 in preparation of a medicine for preventing and / or treating sleep apnea complicated with heart failure. Experiments show that the GANT61 can improve cardiac function reduction induced by intermittent hypoxia combined with angiotensin II, reduce ventricular remodeling and myocardial fibrosis induced by intermittent hypoxia combined with angiotensin II, inhibit the multiplication capacity of cardiac fibroblasts, inhibit differentiation of cardiac fibroblasts induced by intermittent hypoxia to myofibroblasts, improve the cardiac function reduction induced by intermittent hypoxia combined with angiotensin II, and improve the cardiac function reduction induced by intermittent hypoxia combined with angiotensin II. Intermittent hypoxia-induced cardiac fibroblasts are inhibited from secreting extracellular matrixes, and the weight, blood pressure, heart rate and renal functions are not affected.

The invention relates to the technical field of biological medicines, and particularly discloses application of sarcosine in preparation of a medicine for treating ischemic heart disease. According to the technical scheme provided by the invention, the expression of HIF1-alpha protein can be remarkably increased through sarcosine, so that angiogenesis is enhanced, the heart function of the ischemic heart disease is improved, ventricular remodeling is relieved, and the ischemic heart disease can be effectively prevented and / or treated.

The invention relates to the technical field of biological medicine, in particular to application of glucosylceramide level as a diagnosis and treatment target of heart failure. According to the invention, key pathological cascade reactions such as lysosomal membrane permeabilization, cathepsin leakage, mitochondrial dysfunction and the like in the occurrence and development process of heart failure are blocked from the source by reducing the level of glucosylceramide in myocardial tissues. By inhibiting synthesis of glucosylceramide or enhancing degradation in lysosome of glucosylceramide, glucosylceramide abnormally accumulated in myocardial cells is removed, organelle structures and energy metabolism states are remarkably improved, and then myocardial contraction and relaxation functions are improved. In an animal model, the strategy can reverse ventricular remodeling, improve ejection fraction and relieve cardiac hypertrophy and fibrosis. In addition, the glucosylceramide detection method provided by the invention can be used for assisting in evaluating metabolic abnormalities related to heart failure, so that disease judgment is more accurate.

The invention relates to an application of a heart expanding prescription in preparation of a medicine for treating ventricular remodeling and myocardial apoptosis of dilated cardiomyopathy, and relates to an application of a heart expanding prescription in preparation of a medicine for improving gap junction remodeling. By observing the protective effect of the heart dilation prescription on doxorubicin-induced dilated cardiomyopathy rat ventricular remodeling and myocardial cell apoptosis and exploring the action mechanism of the heart dilation prescription, it is proved that the heart dilation prescription can improve doxorubicin-induced dilated cardiomyopathy ventricular remodeling and myocardial cell apoptosis; the mechanism may be related to regulation and control of gap connection reconstruction mediated by an ASK1 / JNK / Cx43 signal channel. In addition, by down-regulating an ASK1 / JNK / Cx43 pathway and improving gap connection reconstruction, the heart expanding formula can significantly inhibit DOX-induced H9c2 cell apoptosis.

The invention discloses application of mesenchymal stem cell spheres in preparation of medicines for treating pulmonary arterial hypertension, and relates to the technical field of biological medicines. According to the application of the mesenchymal stem cell spheres in preparation of the medicine for treating pulmonary arterial hypertension, the pulmonary arterial pressure of mice can be reduced, lung tissue collagen deposition can be reduced to relieve pulmonary fibrosis, myocardial hypertrophy and right ventricular remodeling are inhibited, pulmonary vascular endothelial injury is improved, and integrity is enhanced; meanwhile, infiltration of inflammatory cells such as macrophages, mononuclear cells and neutrophils in lung tissues is inhibited, and circulating inflammatory response is regulated. The invention provides a novel therapeutic scheme for repairing blood vessels, regulating immunity and improving pathological remodeling for pulmonary arterial hypertension, and has clinical application potential.

The invention discloses a preparation method of a traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparation of a medicine for preventing and treating hypertrophic cardiomyopathy, and belongs to the technical field of traditional Chinese medicines. The technical problem to be solved is to provide the traditional Chinese medicine for treating dilated cardiomyopathy, atherosclerotic plaque, myocardial fibrosis, ventricular remodeling, senile cardiac metabolic disorder, hypertrophic cardiomyopathy, hypertrophic cardiomyopathy and hypertrophic cardiomyopathy aiming at the defects of the prior art in preparation of medicines for preventing and treating hypertrophic cardiomyopathy. The invention also discloses application of the traditional Chinese medicine composition in preparation of medicines for treating hypertrophic cardiomyopathy, wherein the traditional Chinese medicine composition has the effects of improving cardiac degeneration of mice with myocardial hypertrophy induced by blood constriction. According to the key point of the technical scheme, the invention provides the application of the traditional Chinese medicine composition in preparing the medicine for preventing and treating hypertrophic cardiomyopathy. The traditional Chinese medicine composition comprises the following raw materials: American ginseng, ginseng, astragalus membranaceus, spina date seeds, salvia miltiorrhiza, pseudo-ginseng, fingered citron and mangnolia officinalis.

The application belongs to the technical field of biological medicine, and specifically discloses a new use of Areg. The application discloses the following: a preparation for promoting expression of Areg or Areg protein is used for preparing a drug for preventing and treating myocardial infarction; the preparation for promoting expression of Areg or Areg protein is used for preparing a drug for preventing and treating heart dysfunction; a preparation for inhibiting expression of Areg is used for preparing a biological model of myocardial infarction or a biological model of adverse ventricular remodeling; a preparation for detecting expression level of Areg is used for preparing a product for screening (diagnosing) myocardial infarction. It is found that expression of Areg protein is increased after myocardial infarction of a mouse, and it is found that knocking out Areg can aggravate adverse ventricular remodeling after myocardial infarction of a mouse. It is verified that by increasing expression level of Areg protein, autophagosome formation is inhibited, myocardial cell apoptosis is reduced, loss of functional myocardial cells is reduced, thereby ventricular remodeling is improved, and heart function is protected.

The application discloses a kind of adipose tissue-derived mitochondrial-derived vesicles and its preparation method and application, belong to the field of biological medicine.The preparation method includes obtaining mouse adipose tissue, including at least one of interscapular brown adipose tissue, epididymal white adipose tissue, beige adipose tissue, in vitro cultured adipocyte;Mouse adipose tissue homogenate is removed by differential centrifugation Unbroken cell, nucleus, mitochondrial and organelle precipitate, the supernatant obtained is treated by trypsin and then ultracentrifuged, the precipitate is collected, washed, to obtain mitochondrial-derived vesicles, which are membrane-coated vesicles, with a particle size of 100-200 nm, enriched in mitochondrial membrane proteins and oxidative phosphorylation-related proteins, and proved by ischemic heart disease model that it can improve heart function, reduce the degree of ventricular remodeling in mice with ischemic heart disease and reduce the fibrosis area, for the preparation of drugs for preventing or treating ischemic heart disease, and has important clinical application value.